ACETAMINOPHEN$DB00316$Gleevec$DB00619$Systemic exposure to acetaminophen is expected to be increased when coadministered with Gleevec.| 
ACITRETIN$DB00459$ALCOHOL$DB00898$Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and ethanol.| 
ACITRETIN$DB00459$Glibenclamide$DB01016$Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.| 
ACITRETIN$DB00459$PHENYTOIN$DB00252$Phenytoin: If acitretin is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.| 
ADENOSINE PHOSPHATE$DB00415$ALLOPURINOL$DB00437$Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| 
ADENOSINE$DB00640$CAFFEINE$DB00201$The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.| 
ADENOSINE$DB00640$DIPYRIDAMOLE$DB00975$Adenosine effects are potentiated by dipyridamole.| Thus, smaller doses of adenosine may be effective in the presence of dipyridamole.| 
ADENOSINE$DB00640$THEOPHYLLINE$DB00277$The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline.| 
Adrenaline$DB00668$Fluothane$DB01159$Caution should be exercised during the administration of adrenaline to patients anaesthetised with FLUOTHANE as arrhythmias may be precipitated.| 
Albuterol$DB01001$Albuterol$DB01001$Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.| 
ALCOHOL$DB00898$Abilify$DB01238$As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY| 
ALCOHOL$DB00898$Antizol$DB01213$Similarly, ethanol decreased the rate of elimination of Antizol (by approximately 50%) by the same mechanism.| 
ALCOHOL$DB00898$ASPIRIN$DB00945$Alcohol: Has a synergistic effect with aspirin in causing gastrointestinal bleeding.| 
ALCOHOL$DB00898$Romazicon$DB01205$Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.| 
ALCOHOL$DB00898$TRIAZOLAM$DB00897$Because of the possible additive effects of drugs that may depress the nervous system, ethanol or triazolam should be used cautiously in combination with tiagabine.| 
ALCOHOL$DB00898$Wellbutrin$DB01156$The consumption of alcohol during treatment with WELLBUTRIN should be minimized or avoided (also see  a href= bupropz_od.htm#CI CONTRAINDICATIONS)| 
Alfentanyl$DB00802$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
Alfentanyl$DB00802$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
ALISKIREN$DB01258$FUROSEMIDE$DB00695$Furosemide When aliskiren was co-administered with furosemide, the AUC and Cmax of furosemide were reduced by about 30% and 50%, respectively.| 
ALLOPURINOL$DB00437$ADENOSINE PHOSPHATE$DB00415$The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| 
ALLOPURINOL$DB00437$AMPICILLIN$DB00415$The concurrent administration of allopurinol and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.| 
ALLOPURINOL$DB00437$AZATHIOPRINE$DB00993$Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| 
ALLOPURINOL$DB00437$CHLORPROPAMIDE$DB00672$The risk of hypoglycemia secondary to this mechanism may be increased if allopurinol and chlorpropamide are given concomitantly in the presence of renal insufficiency.| 
ALLOPURINOL$DB00437$DICUMAROL$DB00266$The clinical basis of this drug interaction has not been established but should be noted when allopurinol is given to patients already on dicumarol therapy.| 
ALLOPURINOL$DB00437$MERCAPTOPURINE$DB01033$In patients receiving mercaptopurine (Purinethol) or azathioprine (Imuran), the concomitant administration of 300-600 mg of allopurinol per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine.| Mercaptopurine/Azathioprine: Allopurinol inhibits the enzymatic oxidation of mercaptopurine and azathioprine to 6-thiouric acid.| 
ALLOPURINOL$DB00437$Videx$DB00900$Allopurinol: The AUC of didanosine was increased about 4-fold when allopurinol at 300 mg/day was coadministered with a single 200-mg dose of VIDEX to two patients with renal impairment (CLcr=15 and 18 mL/min).| 
ALMOTRIPTAN$DB00918$Ketoconazole$DB01026$Ketoconazole and Other Potent CYP3A4 Inhibitors Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.| 
ALMOTRIPTAN$DB00918$Verapamil$DB00661$Verapamil Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.| 
ALPRAZOLAM$DB00404$ALCOHOL$DB00898$The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.| 
ALPRAZOLAM$DB00404$APREPITANT$DB00673$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| 
ALPRAZOLAM$DB00404$DIGOXIN$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
ALPRAZOLAM$DB00404$FLUVOXAMINE$DB00176$Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.| Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
ALPRAZOLAM$DB00404$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
ALPRAZOLAM$DB00404$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
ALUMINUM HYDROXIDE$DB06723$ENOXACIN$DB00467$Antacids containing aluminum hydroxide and magnesium hydroxide reduce the oral absorption of enoxacin by 75%.| 
AMILORIDE$DB00594$DOFETILIDE$DB00204$In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| 
AMINOCAPROIC ACID$DB00513$NovoSeven$DB00036$Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.| 
AMIODARONE$DB01118$DIGOXIN$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
AMIODARONE$DB01118$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
AMIODARONE$DB01118$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
AMIODARONE$DB01118$Tikosyn$DB00204$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
AMOXAPINE$DB00543$ALCOHOL$DB00898$Amoxapine may enhance the response to alcohol and the effects of barbiturates and other CNS depressants.| 
AMPHOTERICIN B$DB00681$HYDROCORTISONE$DB00741$In addition, there have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.| 
AMPICILLIN$DB00415$ALLOPURINOL$DB00437$Ampicillin/Amoxicillin: An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs.| 
AMPRENAVIR$DB00701$RITONAVIR$DB00503$Appropriate laboratory testing should be considered prior to initiating combination therapy with Amprenavir and ritonavir and at periodic intervals or if any clinical signs or symptoms of hyperlipidemia or elevated liver function tests occur during therapy.| Laboratory Tests: The combination of Amprenavir and low-dose ritonavir has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.| 
Anafranil$DB01242$DIGOXIN$DB00390$Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.| 
ANAGRELIDE$DB00261$ASPIRIN$DB00945$Anagrelide alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by aspirin.| 
ANAGRELIDE$DB00261$Cyclic AMP$DB02527$Anagrelide is an inhibitor of cyclic AMP PDE III.| 
ANASTROZOLE$DB01217$TAMOXIFEN$DB00675$Co-administration of anastrozole and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.| 
Antizol$DB01213$ALCOHOL$DB00898$Oral doses of Antizol (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses.| 
Antizol$DB01213$CARBAMAZEPINE$DB00564$Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| 
Antizol$DB01213$Ketoconazole$DB01026$Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied| 
APOMORPHINE$DB00714$ALOSETRON$DB00969$5HT3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| 
APOMORPHINE$DB00714$DOLASETRON$DB00757$5HT3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .| 
APREPITANT$DB00673$CARBAMAZEPINE$DB00564$therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.| 
APREPITANT$DB00673$DEXAMETHASONE$DB01234$Corticosteroids: Dexamethasone: Aprepitant, when given as a regimen of 125mg with dexamethasone coadministered orally as 20 mg on Day 1, and Aprepitant when given as 80 mg/day with dexamethasone coadministered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.| 
APREPITANT$DB00673$METHYLPREDNISOLONE$DB00959$Aprepitant, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.| 
APREPITANT$DB00673$MIDAZOLAM$DB00683$Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.| Midazolam: Aprepitant increased the AUC of midazolam, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of midazolam 2 mg was coadministered on Day 1 and Day 5 of a regimen of Aprepitant 125 mg on Day 1 and 80 mg/day on Days 2 through 5.| 
APREPITANT$DB00673$PHENYTOIN$DB00252$Coadministration of Aprepitant with these drugs or other drugs that are known to be metabolized by CYP2C9, such as phenytoin, may result in lower plasma concentrations of these drugs.| 
APREPITANT$DB00673$RIFAMPIN$DB01045$Rifampin: When a single 375-mg dose of Aprepitant was administered on Day9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold.| 
APREPITANT$DB00673$RITONAVIR$DB00503$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
APREPITANT$DB00673$TOLBUTAMIDE$DB01124$Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.| 
APREPITANT$DB00673$TROLEANDOMYCIN$DB01361$Consequently, concomitant administration of Aprepitant with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir) should be approached with caution.| 
ARIPIPRAZOLE$DB01238$QUINIDINE$DB00908$Quinidine: Coadministration of a 10-mg single dose of aripiprazole with quinidine (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%.| 
ASPIRIN$DB00945$Celebrex$DB00482$However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.| 
ASPIRIN$DB00945$Fenoprofen$DB00573$The coadministration of aspirin decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.| 
ASPIRIN$DB00945$Nalfon$DB00573$Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.| 
ASPIRIN$DB00945$Nicotinic Acid$DB00627$Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid.| 
ASPIRIN$DB00945$NIZATIDINE$DB00585$In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when nizatidine, 150 mg b.i.d., was administered concurrently.| 
ASPIRIN$DB00945$PHENYLBUTAZONE$DB00812$Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| 
ASPIRIN$DB00945$PROBENECID$DB01032$Uricosuric Agents: Aspirin may decrease the effects of probenecid, sulfinpyrazone, and phenylbutazone.| 
ASPIRIN$DB00945$VALDECOXIB$DB00580$Aspirin: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.| 
ASPIRIN$DB00945$Vioxx$DB00533$Aspirin Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.| 
ASTEMIZOLE$DB00637$Ketoconazole$DB01026$Coadministration of astemizole with ketoconazole tablets is therefore contraindicated.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| 
ATORVASTATIN$DB01076$ALISKIREN$DB01258$Co-administration of atorvastatin resulted in about a 50% increase in aliskiren Cmax and AUC after multiple dosing.| 
ATORVASTATIN$DB01076$CIMETIDINE$DB00501$Cimetidine: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.| 
ATORVASTATIN$DB01076$DIGOXIN$DB00390$Digoxin: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.| 
ATORVASTATIN$DB01076$ERYTHROMYCIN$DB00199$Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.| 
Atromid-S$DB00636$TOLBUTAMIDE$DB01124$Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from their binding sites.| 
AURANOFIN$DB00995$Cuprimine$DB00859$Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| 
AURANOFIN$DB00995$PENICILLAMINE$DB00859$Auranofin should not be used together with penicillamine (Depen, Cuprimine), another arthritis medication.| 
AZATHIOPRINE$DB00993$ALLOPURINOL$DB00437$Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.| Use with Allopurinol: The principal pathway for detoxification of azathioprine is inhibited by allopurinol.| 
Betaseron$DB00068$ANTIPYRINE$DB01435$Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.| 
BEXAROTENE$DB00307$GEMFIBROZIL$DB01241$Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| 
Bextra$DB00580$LITHIUM CATION$DB01356$Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.| 
Bextra$DB00580$LITHIUM$DB01356$Lithium serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving lithium.| 
Bezalip$DB01393$COUMARIN$DB04665$When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.| 
BISMUTH SUBSALICYLATE$DB01294$ENOXACIN$DB00467$Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.| 
BOSENTAN ANHYDROUS$DB00559$ATORVASTATIN$DB01076$Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| 
BOSENTAN ANHYDROUS$DB00559$GLYBURIDE$DB01016$Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.| 
BOSENTAN ANHYDROUS$DB00559$LOVASTATIN$DB00227$Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| 
BOSENTAN ANHYDROUS$DB00559$SIMVASTATIN$DB00641$Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active ?-hydroxy acid metabolite, by approximately 50%.| 
BOSENTAN$DB00559$ATORVASTATIN$DB01076$Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| 
BOSENTAN$DB00559$GLYBURIDE$DB01016$Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.| 
BOSENTAN$DB00559$LOVASTATIN$DB00227$Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.| 
BOSENTAN$DB00559$SIMVASTATIN$DB00641$Simvastatin and Other Statins: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active ?-hydroxy acid metabolite, by approximately 50%.| 
Brevibloc$DB00187$DIGOXIN$DB00390$Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| 
Brevibloc$DB00187$DOPAMINE$DB00988$Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| 
Brevibloc$DB00187$EPINEPHRINE$DB00668$Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| 
Brevibloc$DB00187$MORPHINE$DB00295$When intravenous morphine and BREVIBLOC were concomitantly administered in normal subjects, no effect on morphine blood levels was seen, but BREVIBLOC steady-state blood levels were increased by 46% in the presence of morphine.| 
Brevibloc$DB00187$NOREPINEPHRINE$DB00368$Additionally, BREVIBLOC should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as dopamine, epinephrine, and norepinephrine because of the danger of blocking cardiac contractility when systemic vascular resistance is high.| 
Brevibloc$DB00187$SUCCINYLCHOLINE$DB00202$Although the interactions observed in these studies do not appear to be of major clinical importance, BREVIBLOC should be titrated with caution in patients being treated concurrently with digoxin, morphine, succinylcholine or warfarin.| 
Brevibloc$DB00187$Verapamil$DB00661$Caution should be exercised when considering the use of BREVIBLOC and verapamil in patients with depressed myocardial function.| 
BUPRENORPHINE$DB00921$Levo-Dromoran$DB00854$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
BUPRENORPHINE$DB00921$Subutex$DB00921$In many of these cases, buprenorphine was misused by self-injection of crushed SUBUTEX tablets.| 
BUSPIRONE$DB00490$DIGOXIN$DB00390$In vitro, buspirone may displace less firmly bound drugs like digoxin.| 
BUSULFAN$DB01008$ACETAMINOPHEN$DB00316$Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.| 
BUSULFAN$DB01008$Busulfex$DB01008$Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to ( 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues.| 
Busulfex$DB01008$PHENYTOIN$DB00252$Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.| 
BUTORPHANOL$DB00611$ALCOHOL$DB00898$Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.| 
BUTORPHANOL$DB00611$Levo-Dromoran$DB00854$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
CAFFEINE$DB00201$CAFFEINE$DB00201$Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.| 
CAFFEINE$DB00201$CIMETIDINE$DB00501$Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| 
CAFFEINE$DB00201$CLOZAPINE$DB00363$Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| 
CAFFEINE$DB00201$ENOXACIN$DB00467$Caffeine-related adverse effects have occurred in patients consuming caffeine while on therapy with enoxacin.| Trough plasma enoxacin levels were also 20% higher when caffeine and enoxacin were administered concomitantly.| 
CAFFEINE$DB00201$Ketoconazole$DB01026$Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| 
CAFFEINE$DB00201$PHENOBARBITAL$DB01174$Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| 
CAFFEINE$DB00201$PHENYTOIN$DB00252$Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).| 
CAFFEINE$DB00201$THEOBROMINE$DB01412$Caffeine Theobromine Grepafloxacin, like other quinolones, may inhibit the metabolism of caffeine and theobromine.| 
CALCITRIOL$DB00136$Rocaltrol$DB00136$Since blood level of calcitriol/ergocalcitriol will be reduced, higher doses of Rocaltrol may be necessary if these drugs are administered simultaneously.| 
CALCIUM$DB01373$ALENDRONIC ACID$DB00630$Products containing calcium and other multivalent cations likely will interfere with absorption of alendronate.| 
CALCIUM$DB01373$Emcyt$DB01196$Milk, milk products, and calcium-rich foods or drugs may impair the absorption of EMCYT.| 
CAPTOPRIL$DB01197$ALDOSTERONE$DB04630$Agents Increasing Serum Potassium Since captopril decreases aldosterone production, elevation of serum potassium may occur.| 
CARBAMAZEPINE$DB00564$ARIPIPRAZOLE$DB01238$Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.| When carbamazepine is added to aripiprazole therapy, aripiprazole dose should be doubled.| When carbamazepine is withdrawn from the combination therapy, aripiprazole dose should then be reduced.| 
CARBAMAZEPINE$DB00564$CLONAZEPAM$DB01068$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| 
CARBAMAZEPINE$DB00564$DOXYCYCLINE$DB00254$Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| 
CARBAMAZEPINE$DB00564$ESCITALOPRAM OXALATE$DB01175$Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.| 
CARBAMAZEPINE$DB00564$ESCITALOPRAM$DB01175$Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered.| 
CARBAMAZEPINE$DB00564$ESTAZOLAM$DB01215$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| 
CARBAMAZEPINE$DB00564$EXEMESTANE$DB00990$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.| 
CARBAMAZEPINE$DB00564$FELBAMATE$DB00949$The carbamazepine steady-state Cmin decreased 31% to 5?1 micrograms/mL when felbamate (3000 mg/day, divided into three doses) was coadministered.| 
CARBAMAZEPINE$DB00564$LITHIUM CATION$DB01356$Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.| 
CARBAMAZEPINE$DB00564$LITHIUM$DB01356$Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.| 
CARBAMAZEPINE$DB00564$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
CARBAMAZEPINE$DB00564$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
Celebrex$DB00482$FLUCONAZOLE$DB00196$CELEBREX should be introduced at the lowest recommended dose in patients receiving fluconazole.| 
CELECOXIB$DB00482$FLUCONAZOLE$DB00196$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| This increase is due to the inhibition of celecoxib metabolism via P450 2C9 by fluconazole (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).| 
CELECOXIB$DB00482$LITHIUM CATION$DB01356$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| 
CELECOXIB$DB00482$LITHIUM$DB01356$Clinical studies with celecoxib have identified potentially significant interactions with fluconazole and lithium.| 
CEPHALEXIN ANHYDROUS$DB00567$METFORMIN$DB00331$Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Metformin In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| 
CEPHALEXIN ANHYDROUS$DB00567$PROBENECID$DB01032$Probenecid As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| 
CEPHALEXIN$DB00567$METFORMIN$DB00331$Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin.| Although not observed in this study, adverse effects could potentially arise from co-administration of cephalexin and metformin by inhibition of tubular secretion via organic cationic transporter systems.| Metformin In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.| 
CEPHALEXIN$DB00567$PROBENECID$DB01032$Probenecid As with other b-lactams, the renal excretion of cephalexin is inhibited by probenecid.| 
CHLOROTRIANISENE$DB00269$ASPIRIN$DB00945$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$BROMOCRIPTINE$DB01200$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$CALCIUM$DB01373$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$CYCLOSPORINE$DB00091$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$DANTROLENE$DB01219$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$NICOTINE$DB00184$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$Somatropin$DB00052$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLOROTRIANISENE$DB00269$TAMOXIFEN$DB00675$Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.| 
CHLORPROMAZINE$DB00477$AMITRIPTYLINE$DB00321$The concurrent use of two or more drugs with anticholinergic activity--such as an antipsychotic drug (eg, chlorpromazine), an antiparkinsonian drug (eg, trihexyphenidyl), and/or a tricyclic antidepressant (eg, amitriptyline)--commonly results in excessive anticholinergic effects, including dry mouth and associated dental complications, blurred vision, and, in patients exposed to high temperature and humidity, hyperpyrexia.| 
CHLORPROMAZINE$DB00477$DOPAMINE$DB00988$Chlorpromazine - Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.| Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.| 
CHLORPROMAZINE$DB00477$NOREPINEPHRINE$DB00368$Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.| 
CHLORPROPAMIDE$DB00672$ALLOPURINOL$DB00437$Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.| 
CHLORPROTHIXENE$DB01239$LITHIUM CATION$DB01356$Chlorprothixene may increase the plasma-level of concomitantly given lithium.| 
CHLORPROTHIXENE$DB01239$LITHIUM$DB01356$Chlorprothixene may increase the plasma-level of concomitantly given lithium.| 
CICLESONIDE$DB01410$Ketoconazole$DB01026$In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.| 
CILOSTAZOL$DB01166$DILTIAZEM$DB00343$Population pharmacokinetic studies showed higher concentrations of cilostazol among patients concurrently treated with diltiazem, an inhibitor of C.P.A..| 
CIMETIDINE$DB00501$Alfenta$DB00802$Cimetidine reduces the clearance of ALFENTA.| 
CIMETIDINE$DB00501$Cisapride$DB00604$H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.| The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.| 
CIMETIDINE$DB00501$CLOZAPINE$DB00363$Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| 
CIMETIDINE$DB00501$DILTIAZEM$DB00343$A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and AUC (53%) after a 1-week course of cimetidine 1200 mg/day and a single dose of diltiazem 60mg.| 
CIMETIDINE$DB00501$DOFETILIDE$DB00204$Cimetidine at doses of 100 mg BID (OTC dose) resulted in a 13% increase in dofetilide plasma levels (500 mcg single dose).| 
CIMETIDINE$DB00501$Ellence$DB00445$Cimetidine treatment should be stopped during treatment with ELLENCE.| 
CIMETIDINE$DB00501$EPIRUBICIN$DB00445$Cimetidine increased the AUC of epirubicin by 50%.| 
CIMETIDINE$DB00501$GABAPENTIN$DB00996$Cimetidine: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.| Thus cimetidine appeared to alter the renal excretion of both gabapentin and creatinine, an endogenous marker of renal function.| 
CIMETIDINE$DB00501$Tikosyn$DB00204$Cimetidine at 400 mg BID (the usual prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide plasma levels by 58%.| 
CINACALCET$DB01012$AMITRIPTYLINE$DB00321$Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.| 
CIPROFLOXACIN$DB00537$CAFFEINE$DB00201$Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.| 
CIPROFLOXACIN$DB00537$CYCLOSPORINE$DB00091$Some quinolones, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.| 
CIPROFLOXACIN$DB00537$DIDANOSINE$DB00900$In a single subject given one dose of ciprofloxacin 2 hours after a dose of didanosine-placebo tablets, a greater than 50% reduction in the AUC of ciprofloxacin was observed.| The AUC of ciprofloxacin was decreased an average of 15-fold in 12 healthy subjects given ciprofloxacin and didanosine-placebo tablets concurrently.| 
CIPROFLOXACIN$DB00537$IRON$DB01592$Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
CIPROFLOXACIN$DB00537$MAGNESIUM CATION$DB01378$Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
CIPROFLOXACIN$DB00537$MAGNESIUM$DB01378$Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
CIPROFLOXACIN$DB00537$THEOPHYLLINE$DB00277$Theophylline As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.| 
CIPROFLOXACIN$DB00537$Videx$DB00900$Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
CIPROFLOXACIN$DB00537$ZINC$DB01593$Multivalent Cation-Containing Products Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.| 
Cisapride$DB00604$Ketoconazole$DB01026$A study in 14 normal male and female volunteers suggests that coadministration of cisapride and ketoconazole can result in prolongation of the QT interval on the ECG.| Terfenadine, astemizole and cisapride are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that ketoconazole, a potent inhibitor of IIIA4, blocks the metabolism of these drugs, resulting in increased plasma concentrations of parent drug.| 
CLARITHROMYCIN$DB01211$AMOXICILLIN ANHYDROUS$DB01060$Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.| 
CLARITHROMYCIN$DB01211$AMOXICILLIN$DB01060$Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.| 
CLARITHROMYCIN$DB01211$Cisapride$DB00604$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
CLARITHROMYCIN$DB01211$DIGOXIN$DB00390$Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| 
CLARITHROMYCIN$DB01211$NEVIRAPINE$DB00238$Clarithromycin exposure was significantly decreased by nevirapine;| 
CLARITHROMYCIN$DB01211$PIMOZIDE$DB01100$Concomitant administration of clarithromycin with pimozide is contraindicated.| 
CLOMIPRAMINE$DB01242$PHENYTOIN$DB00252$Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.| 
CLOMIPRAMINE$DB01242$PRIMIDONE$DB00794$Agents with Increased Levels in the Presence of Carbamazepine: EQUETROTM increases the plasma levels of the following agents: Clomipramine HCl, Phenytoin(6), and primidone Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with EQUETROTM, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.| 
CLONAZEPAM$DB01068$PROPANTHELINE$DB00782$In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.| 
CLOZAPINE$DB00363$Atropine$DB00572$Clozapine may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of atropine-type drugs.| 
CLOZAPINE$DB00363$CARBAMAZEPINE$DB00564$Although concomitant use of Clozapine and carbamazepine is not recommended, it should be noted that discontinuation of concomitant carbamazepine administration may result in an increase in Clozapine plasma levels.| Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| 
CLOZAPINE$DB00363$Encainide$DB01228$Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| 
CLOZAPINE$DB00363$PAROXETINE$DB00715$However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| 
CLOZAPINE$DB00363$QUINIDINE$DB00908$Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.| 
CLOZAPINE$DB00363$SERTRALINE$DB01104$However, other published reports describe modest elevations (less than two-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.| 
COCAINE$DB00907$DIACETYLMORPHINE$DB01452$Cocaine sometimes proves to be fatal when used in combination with heroin.| 
COLCHICINE$DB01394$Vitamin B12$DB00115$Colchicine para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.| 
Copegus$DB00811$DIDANOSINE$DB00900$Nucleoside Analogues Didanosine Co-administration of COPEGUS and didanosine is not recommended.| 
Crixivan$DB00224$ATAZANAVIR$DB01072$Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.| 
Crixivan$DB00224$DELAVIRDINE$DB00705$Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.| 
Cyclophosphamide$DB00531$ALLOPURINOL$DB00437$Cytotoxic Agents: Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease, except leukemia, in the presence of allopurinol.| 
Cyclophosphamide$DB00531$PHENOBARBITAL$DB01174$The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.| 
Cyclosporin A$DB00091$ETOPOSIDE$DB00773$High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.| 
CYCLOSPORINE$DB00091$CYCLOSPORINE$DB00091$Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly.| 
CYCLOSPORINE$DB00091$DILTIAZEM$DB00343$If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued.| 
CYCLOSPORINE$DB00091$NORFLOXACIN$DB01059$Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin.| 
CYCLOSPORINE$DB00091$PENTAMIDINE$DB00738$Other nephrotoxic medications: agents such as aminoglycosides, cyclosporine, and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.| 
CYCLOSPORINE$DB00091$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
CYCLOSPORINE$DB00091$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
Cytadren$DB00357$DEXAMETHASONE$DB01234$Cytadren accelerates the metabolism of dexamethasone;| 
Cytosine arabinoside$DB00987$FLUCYTOSINE$DB01099$Cytosine arabinoside, a cytostatic agent, has been reported to inactivate the antifungal activity of flucytosine by competitive inhibition.| 
d-amphetamine$DB01576$DESIPRAMINE$DB01151$d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| 
d-amphetamine$DB01576$PROTRIPTYLINE$DB00344$d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;| 
DANAZOL$DB01406$LOVASTATIN$DB00227$Danazol: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol particularly with higher doses of lovastatin (see WARNINGS, Myopathy/Rhabdomyolysis).| 
DANTROLENE$DB01219$VECURONIUM$DB01339$Administration of dantrolene may potentiate vecuronium-induced neuromuscular block.| 
DAPSONE$DB00250$PYRIMETHAMINE$DB00205$With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions| 
DAPSONE$DB00250$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
DAPSONE$DB00250$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
DELAVIRDINE$DB00705$Videx$DB00900$Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| 
DEXAMETHASONE$DB01234$ALBENDAZOLE$DB00518$Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.| 
DEXAMETHASONE$DB01234$APREPITANT$DB00673$The daily dose of dexamethasone administered in clinical studies with Aprepitant reflects an approximate 50% reduction of the dose of dexamethasone.| 
DEXAMETHASONE$DB01234$SAQUINAVIR MESYLATE$DB01232$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
DEXAMETHASONE$DB01234$SAQUINAVIR$DB01232$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
DEXBROMPHENIRAMINE$DB00405$ALCOHOL$DB00898$Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).| 
DIACETYLMORPHINE$DB01452$ALCOHOL$DB00898$Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| 
DIACETYLMORPHINE$DB01452$DIAZEPAM$DB00829$Toxicology studies of heroin-related deaths reveal frequent involvement of other central nervous system depressants, including alcohol, benzodiazepines such as diazepam (Valium), and, to a rising degree, methadone.| 
DIAZEPAM$DB00829$FLUVOXAMINE$DB00176$Accordingly, diazepam and fluvoxamine should not ordinarily be co-administered.| 
DIAZEPAM$DB00829$VALDECOXIB$DB00580$Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.| 
DIAZOXIDE$DB01119$HYDRALAZINE$DB01275$Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.| 
DICLOFENAC$DB00586$ASPIRIN$DB00945$Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.| 
DICLOFENAC$DB00586$CYCLOSPORINE$DB00091$Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| 
DICLOFENAC$DB00586$DIGOXIN$DB00390$Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine?s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| 
DICLOFENAC$DB00586$LITHIUM CATION$DB01356$In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| 
DICLOFENAC$DB00586$LITHIUM$DB01356$In patients taking diclofenac and lithium concomitantly, lithium toxicity may develop.| 
DICLOFENAC$DB00586$METHOTREXATE$DB00563$Ingestion of diclofenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine?s nephrotoxicity.| Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.| 
DICLOFENAC$DB00586$PREDNISOLONE$DB00860$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| 
DICLOFENAC$DB00586$SALICYLIC ACID$DB00936$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| 
DICLOFENAC$DB00586$TOLBUTAMIDE$DB01124$Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.| 
DICYCLOMINE$DB00804$Cisapride$DB00604$Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.| 
DIFLUNISAL$DB00861$ACETAMINOPHEN$DB00316$Acetaminophen: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.| Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.| Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and acetaminophen should be used cautiously, with careful monitoring of patients.| 
DIFLUNISAL$DB00861$ASPIRIN$DB00945$Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.| 
DIFLUNISAL$DB00861$FUROSEMIDE$DB00695$Diflunisal decreased the hyperuricemic effect of furosemide.| 
DIFLUNISAL$DB00861$HYDROCHLOROTHIAZIDE$DB00999$Diflunisal decreased the hyperuricemic effect of hydrochlorothiazide.| Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.| 
DIFLUNISAL$DB00861$INDOMETHACIN$DB00328$Nonsteroidal Anti-Inflammatory Drugs The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.| 
DIFLUNISAL$DB00861$METHOTREXATE$DB00563$Methotrexate: Caution should be used if diflunisal is administered concomitantly with methotrexate.| 
DIFLUNISAL$DB00861$NAPROXEN$DB00788$Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.| 
DIGOXIN$DB00390$Adenocard$DB00640$Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard.| 
DIGOXIN$DB00390$Brevibloc$DB00187$When digoxin and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.| 
DIGOXIN$DB00390$CONIVAPTAN$DB00872$Digoxin Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.| 
DIGOXIN$DB00390$Cyclophosphamide$DB00531$Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide, vincristine, and prednisone with or without cytarabine or procarbazine.| 
DIGOXIN$DB00390$DOFETILIDE$DB00204$In patients, the concomitant administration of digoxin with dofetilide was associated with a higher occurrence of torsade de pointes.| 
DIGOXIN$DB00390$Flolan$DB01240$However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.| In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| 
DIGOXIN$DB00390$Ketoconazole$DB01026$It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.| 
DIGOXIN$DB00390$PREDNISONE$DB00635$Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide, vincristine, and prednisone with or without cytarabine or procarbazine.| 
DIGOXIN$DB00390$VINCRISTINE$DB00541$Reversible decreases in steady-state plasma digoxin concentrations and renal glycoside excretion were observed in patients receiving beta-acetyl digoxin and chemotherapy regimens containing cyclophosphamide, vincristine, and prednisone with or without cytarabine or procarbazine.| 
DIHYDROERGOTAMINE$DB00320$Frova$DB00998$Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| 
DIHYDROERGOTAMINE$DB00320$NARATRIPTAN$DB00952$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| 
DILTIAZEM$DB00343$CARBAMAZEPINE$DB00564$Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase), resulting in toxicity in some cases.| 
DILTIAZEM$DB00343$CIMETIDINE$DB00501$Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine.| 
DILTIAZEM$DB00343$CYCLOSPORINE$DB00091$A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients.| 
DILTIAZEM$DB00343$FENTANYL$DB00813$The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.| 
DILTIAZEM$DB00343$LOVASTATIN$DB00227$In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;| 
DILTIAZEM$DB00343$MIDAZOLAM$DB00683$Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| 
DILTIAZEM$DB00343$RIFAMPIN$DB01045$Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.| 
DILTIAZEM$DB00343$Tikosyn$DB00204$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
DILTIAZEM$DB00343$TRIAZOLAM$DB00897$Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.| These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and triazolam.| 
DIMENHYDRINATE$DB00985$APOMORPHINE$DB00714$Dimenhydrinate may decrease emetic response to apomorphine.| 
DIPHENOXYLATE$DB01081$DIGOXIN$DB00390$Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| 
DIPYRIDAMOLE$DB00975$ADENOSINE$DB00640$Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine.| 
DIPYRONE$DB04817$ASPIRIN$DB00945$Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| 
DISULFIRAM$DB00822$ALCOHOL$DB00898$In some patients, a disulfiram-like reaction may be produced by the ingestion of alcohol.| Rare cases of a disulfiram-like reaction to alcohol have been reported.| 
DOLASETRON$DB00757$CIMETIDINE$DB00501$Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| 
DOLASETRON$DB00757$RIFAMPIN$DB01045$Blood levels of hydrodolasetron increased 24% when dolasetron was coadministered with cimetidine (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of rifampin (potent inducer of cytochrome P-450) for 7 days.| 
DULOXETINE$DB00476$AMITRIPTYLINE$DB00321$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| 
DULOXETINE$DB00476$DESIPRAMINE$DB01151$When duloxetine was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.| 
DULOXETINE$DB00476$FLUVOXAMINE$DB00176$Inhibitors of CYP1A2: Concomitant use of duloxetine with fluvoxamine, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of duloxetine.| 
DULOXETINE$DB00476$IMIPRAMINE$DB00458$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| 
DULOXETINE$DB00476$NORTRIPTYLINE$DB00540$Therefore, co-administration of Duloxetine with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain antidepressants (tricyclic antidepressants [TCAs], such as nortriptyline, amitriptyline, and imipramine), phenothiazines and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution.| 
Elspar$DB00023$METHOTREXATE$DB00563$Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.| 
Enablex$DB00496$CLARITHROMYCIN$DB01211$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| 
Enablex$DB00496$Ketoconazole$DB01026$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| 
Enablex$DB00496$NELFINAVIR$DB05251$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| 
Enablex$DB00496$RITONAVIR$DB00503$The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .| 
ENALAPRIL$DB00584$LITHIUM CATION$DB01356$A few cases of lithium toxicity have been reported in patients receiving concomitant enalapril/enalapril IV and lithium and were reversible upon discontinuation of both drugs.| It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.| 
ENALAPRIL$DB00584$LITHIUM$DB01356$A few cases of lithium toxicity have been reported in patients receiving concomitant enalapril/enalapril IV and lithium and were reversible upon discontinuation of both drugs.| It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.| 
ENOXACIN$DB00467$BISMUTH SUBSALICYLATE$DB01294$Thus, concomitant administration of enoxacin and bismuth subsalicylate should be avoided.| 
ENOXACIN$DB00467$CAFFEINE$DB00201$In a multiple-dose study, enoxacin caused a dose-related increase in the mean elimination half-life of caffeine, thereby decreasing the clearance of caffeine by up to 80% and leading to a five-fold increase in the AUC and the half-life of caffeine.| 
ENOXACIN$DB00467$DIGOXIN$DB00390$If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.| 
ENOXACIN$DB00467$RANITIDINE$DB00863$The oral bioavailability of enoxacin is reduced by 60% with coadministration of ranitidine.| 
ENOXACIN$DB00467$THEOPHYLLINE$DB00277$Enoxacin interferes with the metabolism of theophylline resulting in a 42% to 74% dose-related decrease in theophylline clearance and a subsequent 260% to 350% increase in serum theophylline levels.| 
ENOXIMONE$DB04880$ANAGRELIDE$DB00261$The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.| 
EPINEPHRINE$DB00668$GUANETHIDINE$DB01170$Epinephrine may antagonize the neuron blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter.| 
EPINEPHRINE$DB00668$Isoproterenol$DB01064$Epinephrine should not be administered concomitantly with other sympathomimetic drugs (such as isoproterenol) because of possible additive effects and increased toxicity.| 
Ergomar$DB00696$Triacetyloleandomycin$DB01361$The effects of ERGOMAR may be potentiated by triacetyloleandomycin which inhibits the metabolism of ergotamine.| 
ERGOTAMINE$DB00696$Frova$DB00998$Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).| 
ERGOTAMINE$DB00696$NARATRIPTAN$DB00952$Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and naratriptan within 24 hours is contraindicated.| 
ERYTHROMYCIN$DB00199$ALFENTANIL$DB00802$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$ASTEMIZOLE$DB00637$Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and astemizole when taken concomitantly.| Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$BEXAROTENE$DB00307$On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| 
ERYTHROMYCIN$DB00199$BROMOCRIPTINE$DB01200$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$CARBAMAZEPINE$DB00564$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$CILOSTAZOL$DB01166$Pharmacokinetic studies have demonstrated that omeprazole and erythromycin significantly increased the systemic exposure of cilostazol and/or its major metabolites.| 
ERYTHROMYCIN$DB00199$Cisapride$DB00604$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| There have been postmarketing reports of drug interactions when erythromycin is coadministered with cisapride, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of cisapride by erythromycin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$CLOZAPINE$DB00363$Cimetidine, caffeine, and erythromycin may increase plasma levels of Clozapine, potentially resulting in adverse effects.| 
ERYTHROMYCIN$DB00199$CYCLOSPORINE$DB00091$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$DIGOXIN$DB00390$Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.| Digoxin Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels.| Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| 
ERYTHROMYCIN$DB00199$DIHYDROERGOTAMINE$DB00320$Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| Ergotamine Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| 
ERYTHROMYCIN$DB00199$ERGOTAMINE$DB00696$Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| Ergotamine Concurrent use of erythromycin and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.| 
ERYTHROMYCIN$DB00199$FENTANYL$DB00813$The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.| 
ERYTHROMYCIN$DB00199$LORATADINE$DB00455$Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of loratadine relative to that observed with erythromycin alone.| 
ERYTHROMYCIN$DB00199$LOVASTATIN$DB00227$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$MIDAZOLAM$DB00683$Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| 
ERYTHROMYCIN$DB00199$PHENYTOIN$DB00252$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$TACROLIMUS ANHYDROUS$DB00864$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$TACROLIMUS$DB00864$There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ERYTHROMYCIN$DB00199$THEOPHYLLINE$DB00277$Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in serum theophylline levels and potential theophylline toxicity.| 
ERYTHROMYCIN$DB00199$TRIAZOLAM$DB00897$Erythromycin has been reported to decrease the clearance of triazolam and midazolam and thus may increase the pharmacologic effect of these benzodiazepines.| 
ERYTHROMYCIN$DB00199$Valproate$DB00313$Other drugs Drug interactions have been reported with concomitant administration of erythromycin and other medications, including cyclosporine, hexobarbital, carbamazepine, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, astemizole, and lovastatin.| There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.| 
ESOMEPRAZOLE$DB00736$AMOXICILLIN ANHYDROUS$DB01060$Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.| 
ESOMEPRAZOLE$DB00736$AMOXICILLIN$DB01060$Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.| 
ESOMEPRAZOLE$DB00736$CLARITHROMYCIN$DB01211$Combination Therapy with Clarithromycin Co-administration of esomeprazole, clarithromycin, and amoxicillin has resulted in increases in the plasma levels of esomeprazole and 14-hydroxyclarithromycin.| 
ESOMEPRAZOLE$DB00736$DIAZEPAM$DB00829$Coadministration of esomeprazole 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.| 
ESOMEPRAZOLE$DB00736$DIGOXIN$DB00390$Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| 
ESOMEPRAZOLE$DB00736$Ketoconazole$DB01026$Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and digoxin).| 
ESTAZOLAM$DB01215$Ketoconazole$DB01026$Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.| 
ESZOPICLONE$DB00402$ALCOHOL$DB00898$CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.| 
ESZOPICLONE$DB00402$Ketoconazole$DB01026$The AUC of eszopiclone was increased 2.2-fold by coadministration of ketoconazole, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.| 
ETHIONAMIDE$DB00609$CYCLOSERINE$DB00260$In particular, convulsions have been reported when ethionamide is administered with cycloserine and special care should be taken when the treatment regimen includes both of these drugs.| 
ETHOXZOLAMIDE$DB00311$PROCAINAMIDE$DB01035$Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.| 
ETHOXZOLAMIDE$DB00311$QUINIDINE$DB00908$Ethoxzolamide may increase the action of tricyclics, amphetamines, procainamide, and quinidine.| 
ETHYLMERCURITHIOSALICYLIC ACID$DB02731$LATANOPROST$DB00654$In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost.| 
Etodolac$DB00749$PHENYLBUTAZONE$DB00812$Although in vivo studies have not been done to see if etodolac clearance is changed by coadministration of phenylbutazone, it is not recommended that they be coadministered.| 
ETONOGESTREL$DB00294$ACETAMINOPHEN$DB00316$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$ADENOSINE PHOSPHATE$DB00415$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Agenerase$DB00701$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$AMPICILLIN$DB00415$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$ASCORBIC ACID$DB00126$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$ATORVASTATIN$DB01076$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Atromid-S$DB00636$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$CLOFIBRATE$DB00636$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Crixivan$DB00224$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$CYCLOSPORINE$DB00091$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Dilantin$DB00252$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Felbatol$DB00949$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Fortovase$DB01232$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Gris-PEG$DB00400$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Invirase$DB01232$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Kadian$DB00295$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Lipitor$DB01076$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$MORPHINE$DB00295$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$MS Contin$DB00295$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Neoral $DB00091$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Nizoral$DB01026$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Norvir$DB00503$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$PHENOBARBITAL$DB01174$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$PHENYLBUTAZONE$DB00812$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$PREDNISOLONE$DB00860$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Prelone$DB00860$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Rifadin$DB01045$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$RIFAMPIN$DB01045$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Sandimmune $DB00091$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Sporanox$DB01167$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$TEGretol$DB00564$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$TETRACYCLINE$DB00759$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Theo-Dur$DB00277$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$THEOPHYLLINE$DB00277$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Topamax$DB00273$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Trileptal$DB00776$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Tylenol$DB00316$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
ETONOGESTREL$DB00294$Viracept$DB00220$Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.| 
FELBAMATE$DB00949$GESTODENE$DB06730$Felbamate treatment resulted in a 42% decrease in the gestodene AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of ethinyl estradiol.| 
FELBAMATE$DB00949$PHENOBARBITAL$DB01174$This indicates that the protein binding of valproate did not change appreciably with increasing doses of Felbatol? Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.| 
FENTANYL$DB00813$ALCOHOL$DB00898$Central Nervous System Depressants The concomitant use of DURAGESIC? (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.| 
FENTANYL$DB00813$CLARITHROMYCIN$DB01211$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
FENTANYL$DB00813$Ketoconazole$DB01026$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
FENTANYL$DB00813$NELFINAVIR$DB05251$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
FENTANYL$DB00813$RITONAVIR$DB00503$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
FENTANYL$DB00813$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
FENTANYL$DB00813$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
FENTANYL$DB00813$TROLEANDOMYCIN$DB01361$The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.| 
Flexeril$DB00924$ALCOHOL$DB00898$FLEXERIL may enhance the effects of alcohol, barbiturates, and other CNS depressants.| 
FLUCONAZOLE$DB00196$CELECOXIB$DB00482$Fluconazole: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.| 
FLUCONAZOLE$DB00196$Cisapride$DB00604$Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
FLUCONAZOLE$DB00196$Ketoconazole$DB01026$Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| 
Fludara$DB01073$PENTOSTATIN$DB00552$The use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended due to the risk of severe pulmonary toxicity.| 
Fluothane$DB01159$TUBOCURARINE$DB01199$FLUOTHANE may augment the hypotension caused by the ganglionic-blocking effect of tubocurarine.| 
FLUVOXAMINE$DB00176$ALPRAZOLAM$DB00404$Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;| Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam.| 
FLUVOXAMINE$DB00176$ASTEMIZOLE$DB00637$Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| 
FLUVOXAMINE$DB00176$Cisapride$DB00604$Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| 
FLUVOXAMINE$DB00176$DIAZEPAM$DB00829$Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.| Diazepam: The co-administration of Fluvoxamine Tablets and diazepam is generally not advisable.| Evidence supporting the conclusion that it is inadvisable to co-administer fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam.| 
FLUVOXAMINE$DB00176$TERBINAFINE$DB00857$Consequently, it is recommended that fluvoxamine not be used in combination with either terbinafine, astemizole, or cisapride.| 
Foscavir$DB00529$AMPHOTERICIN B$DB00681$Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.| 
Foscavir$DB00529$Pentamidin$DB00738$A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described.| Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia;| 
FUROSEMIDE$DB00695$ASPIRIN$DB00945$Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency.| 
FUROSEMIDE$DB00695$ETHACRYNIC ACID$DB00903$Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity.| 
FUROSEMIDE$DB00695$Flolan$DB01240$In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.| 
FUROSEMIDE$DB00695$NOREPINEPHRINE$DB00368$Furosemide may decrease arterial responsiveness to norepinephrine.| 
FUROSEMIDE$DB00695$TUBOCURARINE$DB01199$Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.| 
GABAPENTIN$DB00996$CIMETIDINE$DB00501$This small decrease in excretion of gabapentin by cimetidine is not expected to be of clinical importance.| 
GEMFIBROZIL$DB01241$BEXAROTENE$DB00307$Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| 
GEMFIBROZIL$DB01241$Targretin$DB00307$Concomitant administration of gemfibrozil with Targretin ? capsules is not recommended.| 
Gleevec$DB00619$ACETAMINOPHEN$DB00316$in vitro, Gleevec inhibits acetaminophen O-glucuronidation (Ki value of 58.5 ?M) at therapeutic levels.| 
Gleevec$DB00619$CYCLOSPORINE$DB00091$Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or pimozide).| 
Gleevec$DB00619$ERYTHROMYCIN$DB00199$Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| 
Gleevec$DB00619$Ketoconazole$DB01026$Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).| There is a significant increase in exposure to imatinib when Gleevec is coadministered with ketoconazole (CYP3A4 inhibitor).| 
Gleevec$DB00619$SIMVASTATIN$DB00641$Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.| 
GLIPIZIDE$DB01067$FLUCONAZOLE$DB00196$The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).| 
GLUTAMINE$DB00130$INDOMETHACIN$DB00328$Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.| Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.| 
GLUTAMINE$DB00130$PACLITAXEL$DB01229$Paclitaxel - In one report, L-glutamine at a dose of 10 grams three times daily, given 24 hours after receiving paclitaxel, appeared to prevent the development of myalgia and arthralgia, adverse reactions of paclitaxel.| 
GLUTAMINE$DB02174$INDOMETHACIN$DB00328$Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.| Indomethacin - Concomitant use of L-glutamine and indomethacin may ameliorate increased intestinal permeability caused by indomethacin.| 
GLYBURIDE$DB01016$CIPROFLOXACIN$DB00537$A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.| 
GUANETHIDINE$DB01170$Zebeta$DB00612$Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| 
GUANFACINE$DB01018$PHENOBARBITAL$DB01174$The administration of guanfacine concomitantly with known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration.| 
HALOPERIDOL$DB00502$DOPAMINE$DB00988$Butyrophenones (such as haloperidol) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.| Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.| 
HALOPERIDOL$DB00502$NOREPINEPHRINE$DB00368$Haloperidol: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.| 
HCTZ$DB00999$TRIAMTERENE$DB00384$Hydrochlorothiazide (HCTZ) Alone or in Combination with Triamterene: Concomitant use of HCTZ alone or in combination with triamterene is contraindicated.| In patients receiving HCTZ in combination with triamterene, dofetilide AUC increased by 30% and Cmax by 16%.| 
HYDROCODONE$DB00956$GABAPENTIN$DB00996$Hydrocodone increases gabapentin AUC values by 14%.| 
IMIPRAMINE$DB00458$ALPRAZOLAM$DB00404$The steady state plasma concentrations of imipramine and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.| 
INDINAVIR ANHYDROUS$DB00224$AMPRENAVIR$DB00701$Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.| 
INDINAVIR ANHYDROUS$DB00224$Cisapride$DB00604$Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
INDINAVIR ANHYDROUS$DB00224$DIDANOSINE$DB00900$Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| 
INDINAVIR ANHYDROUS$DB00224$NEVIRAPINE$DB00238$Indinavir concentrations may be decreased in the presence of nevirapine.| 
INDINAVIR ANHYDROUS$DB00224$RITONAVIR$DB00503$Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.| 
INDINAVIR ANHYDROUS$DB00224$Videx$DB00900$Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| 
INDINAVIR$DB00224$AMPRENAVIR$DB00701$Indinavir steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant amprenavir.| 
INDINAVIR$DB00224$Cisapride$DB00604$Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
INDINAVIR$DB00224$DIDANOSINE$DB00900$Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.| 
INDINAVIR$DB00224$NEVIRAPINE$DB00238$Indinavir concentrations may be decreased in the presence of nevirapine.| 
INDINAVIR$DB00224$RITONAVIR$DB00503$Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.| 
INDINAVIR$DB00224$Videx$DB00900$Interactions with Other Antiretroviral Drugs: Significant decreases in the AUC of delavirdine (20%) and indinavir (84%) occurred following simultaneous administration of these agents with VIDEX.| To avoid this interaction, delavirdine or indinavir should be given 1 hour prior to dosing with VIDEX.| 
INDOMETHACIN$DB00328$ALDOSTERONE$DB04630$Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation.| 
INDOMETHACIN$DB00328$BUMETANIDE$DB00887$- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.| 
INDOMETHACIN$DB00328$CAPTOPRIL$DB01197$Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that indomethacin may reduce the antihypertensive effect of captopril, especially in cases of low renin hypertension.| 
INDOMETHACIN$DB00328$DIFLUNISAL$DB00861$In some patients the combined use of indomethacin and diflunisal has been associated with fatal gastrointestinal hemorrhage.| Therefore, indomethacin and diflunisal should not be used concomitantly.| 
INDOMETHACIN$DB00328$DIGOXIN$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
INDOMETHACIN$DB00328$FUROSEMIDE$DB00695$Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis.| Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.| 
INDOMETHACIN$DB00328$Proleukin$DB00041$Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| 
Invirase$DB01232$RITONAVIR$DB00503$Since INVIRASE is coadministered with ritonavir, the ritonavir label should be reviewed for additional drugs that should not be coadministered.| 
IRBESARTAN$DB01029$ALISKIREN$DB01258$Co-administration of irbesartan reduced aliskiren Cmax up to 50% after multiple dosing.| 
Isoflurane$DB00753$Nimbex$DB00565$In long surgical procedures during enflurane or isoflurane anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of NIMBEX may be necessary.| 
ISONIAZID$DB00951$ACETAMINOPHEN$DB00316$Furthermore it has been proposed that isoniazid resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested acetaminophen being converted to the toxic metabolites.| It is believed that the toxicity may have resulted from a previously unrecognized interaction between isoniazid and acetaminophen and a molecular basis for this interaction has been proposed.| 
ISONIAZID$DB00951$CARBAMAZEPINE$DB00564$Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.| 
ISONIAZID$DB00951$Ketoconazole$DB01026$INH (Isoniazid) is also reported to affect ketoconazole concentrations adversely.| 
ISONIAZID$DB00951$LEVODOPA$DB01235$Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.| 
ISONIAZID$DB00951$PHENYTOIN$DB00252$Phenytoin: Isoniazid may increase serum levels of phenytoin.| 
ISONIAZID$DB00951$THEOPHYLLINE$DB00277$Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.| 
ISONIAZID$DB00951$Valproate$DB00313$Plasma valproate concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of valproate should be made.| 
Ketoconazole$DB01026$ALISKIREN$DB01258$Ketoconazole Co-administration of 200 mg twice-daily ketoconazole with aliskiren resulted in an approximate 80% increase in plasma levels of aliskiren.| 
Ketoconazole$DB01026$APREPITANT$DB00673$10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.| 
Ketoconazole$DB01026$ARIPIPRAZOLE$DB01238$Ketoconazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15-mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively.| When concomitant administration of ketoconazole with aripiprazole occurs, aripiprazole dose should be reduced to one-half of its normal dose.| 
Ketoconazole$DB01026$ASTEMIZOLE$DB00637$Pharmacokinetic data indicate that oral ketoconazole inhibits the metabolism of astemizole, resulting in elevated plasma levels of astemizole and its active metabolite desmethylastemizole which may prolong QT intervals.| 
Ketoconazole$DB01026$BEXAROTENE$DB00307$On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.| 
Ketoconazole$DB01026$CICLESONIDE$DB01410$Therefore, ketoconazole should be administered with caution with intranasal ciclesonide.| 
Ketoconazole$DB01026$Cisapride$DB00604$Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| Data suggest that coadministration of oral ketoconazole and cisapride can result in prolongation of the QT interval on the ECG.| Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride.| Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of cisapride.| Therefore concomitant administration of ketoconazole tablets with cisapride is contraindicated.| 
Ketoconazole$DB01026$CYCLOSPORINE$DB00091$Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| 
Ketoconazole$DB01026$ISONIAZID$DB00951$Ketoconazole: Potential interaction of Ketoconazole and Isoniazid may exist.| When Ketoconazole is given in combination with isoniazid and rifampin the AUC of ketoconazole is decreased by as much as 88% after 5 months of concurrent Isoniazid and Rifampin therapy.| 
Ketoconazole$DB01026$METHYLPREDNISOLONE$DB00959$Ketoconazole tablets may alter the metabolism of cyclosporine, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.| 
Ketoconazole$DB01026$PHENYTOIN$DB00252$Concomitant administration of ketoconazole tablets with phenytoin may alter the metabolism of one or both of the drugs.| 
Ketoconazole$DB01026$Sensipar$DB01012$Co-administration of ketoconazole, a strong inhibitor of CYP3A4, increased cinacalcet exposure following a single 90 mg dose of Sensipar by 2.3 fold.| 
Ketoconazole$DB01026$Tikosyn$DB00204$Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.| 
Ketoconazole$DB01026$ZALEPLON$DB00962$Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.| 
LAMIVUDINE$DB00709$ZALCITABINE$DB00943$Lamivudine and zalcitabine may inhibit the intracellular phosphorylation of one another.| Therefore, use of lamivudine in combination with zalcitabine is not recommended| 
Lansoprazole$DB00448$ADENOSINE PHOSPHATE$DB00415$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| 
Lansoprazole$DB00448$AMPICILLIN$DB00415$therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).| 
Lansoprazole$DB00448$THEOPHYLLINE$DB00277$When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.| 
LEVOBUPIVACAINE$DB01002$PHENOBARBITAL$DB01174$Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;| 
LEVODOPA$DB01235$PHENYTOIN$DB00252$In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by phenytoin and papaverine.| 
Levo-Dromoran$DB00854$ALCOHOL$DB00898$Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.| 
Levsin$DB00424$HALOPERIDOL$DB00502$Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.| 
Lexapro$DB01175$ALCOHOL$DB00898$Alcohol - Although LEXAPRO did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by patients taking LEXAPRO is not recommended.| 
Lexapro$DB01175$LITHIUM CATION$DB01356$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| 
Lexapro$DB01175$LITHIUM$DB01356$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| 
LINCOMYCIN$DB01627$ERYTHROMYCIN$DB00199$Antagonism between lincomycin and erythromycin in vitro has been demonstrated.| 
LITHIUM CATION$DB01356$BUMETANIDE$DB00887$- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.| 
LITHIUM CATION$DB01356$Celebrex$DB00482$Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| 
LITHIUM CATION$DB01356$ESCITALOPRAM OXALATE$DB01175$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| 
LITHIUM CATION$DB01356$ESCITALOPRAM$DB01175$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| 
LITHIUM CATION$DB01356$Haldol$DB00502$An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.| 
LITHIUM CATION$DB01356$LITHIUM CATION$DB01356$Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.| Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.| 
LITHIUM CATION$DB01356$LITHIUM$DB01356$Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.| Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.| 
LITHIUM$DB01356$BUMETANIDE$DB00887$- Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.| 
LITHIUM$DB01356$Celebrex$DB00482$Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.| Patients on lithium treatment should be closely monitored when CELEBREX is introduced or withdrawn.| 
LITHIUM$DB01356$ESCITALOPRAM OXALATE$DB01175$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| 
LITHIUM$DB01356$ESCITALOPRAM$DB01175$Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO and lithium are coadministered.| 
LITHIUM$DB01356$Haldol$DB00502$An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus HALDOL.| 
LITHIUM$DB01356$LITHIUM CATION$DB01356$Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.| Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.| 
LITHIUM$DB01356$LITHIUM$DB01356$Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported.| Lithium NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.| 
Lodine$DB00749$ASPIRIN$DB00945$Aspirin When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.| however, as with other NSAIDs, concomitant administration of Lodine and aspirin is not generally recommended because of the potential of increased adverse effects.| 
Lodine$DB00749$FUROSEMIDE$DB00695$Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of furosemide and thiazides in some patients.| 
LORACARBEF ANHYDROUS$DB00447$PROBENECID$DB01032$Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.| 
LORACARBEF$DB00447$PROBENECID$DB01032$Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.| 
LOVASTATIN$DB00227$ERYTHROMYCIN$DB00199$Patients receiving concomitant lovastatin and erythromycin should be carefully monitored;| 
MAGNESIUM CATION$DB01378$Factive$DB01155$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
MAGNESIUM$DB01378$Factive$DB01155$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
MEPERIDINE$DB00454$MEPERIDINE$DB00454$Meperidine - Amphetamines pone the analgesic effect of meperidine.| 
METFORMIN$DB00331$DOFETILIDE$DB00204$In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| 
METHOTREXATE$DB00563$ACETAMINOPHEN$DB00316$Acetaminophen and methotrexate - L-methionine may decrease hepatic toxicity in those with acetaminophen overdosage or in those taking methotrexate.| 
METHOTREXATE$DB00563$ACITRETIN$DB00459$Consequently, the combination of methotrexate with acitretin is also contraindicated.| 
METHOTREXATE$DB00563$CIPROFLOXACIN$DB00537$Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.| Therefore, patients under methotrexate therapy should be carefully monitored when concomitant ciprofloxacin therapy is indicated.| 
METHOTREXATE$DB00563$ETRETINATE$DB00926$Methotrexate: An increased risk of hepatitis has been reported to result from combined use of methotrexate and etretinate.| 
METHOTREXATE$DB00563$Proleukin$DB00041$Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.| 
METHOTREXATE$DB00563$ROFECOXIB$DB00533$At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).| 
METHOTREXATE$DB00563$SULFAPYRIDINE$DB00891$- Methotrexate (e.g., Mexate)?Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate| 
METHYLDOPA$DB00968$SULFAPYRIDINE$DB00891$- Methyldopa (e.g., Aldomet)?Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood| 
METHYLPREDNISOLONE$DB00959$APREPITANT$DB00673$The IV methylprednisolone dose should be reduced by approximately 25%, and the oral methylprednisolone dose should be reduced by approximately 50% when coadministered with Aprepitant to achieve exposures of methylprednisolone similar to those obtained when it is given without Aprepitant.| 
METOCLOPRAMIDE$DB01233$Apokyn$DB00714$Dopamine Antagonists Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenoth-iazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.| 
METOCLOPRAMIDE$DB01233$DIGOXIN$DB00390$Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| 
METOCLOPRAMIDE$DB01233$LEVODOPA$DB01235$Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.| 
MIDAZOLAM$DB00683$APREPITANT$DB00673$The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) should be considered when coadministering these agents with Aprepitant.| 
MIDAZOLAM$DB00683$DILTIAZEM$DB00343$The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.| 
MIDAZOLAM$DB00683$FLUVOXAMINE$DB00176$Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
MOCLOBEMIDE$DB01171$ALMOTRIPTAN$DB00918$Monoamine Oxidase Inhibitors Coadministration of moclobemide resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.| 
Monurol$DB00828$FOSFOMYCIN$DB00828$Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.| 
Nabilone$DB00486$ALCOHOL$DB00898$Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).| 
Nabilone$DB00486$DIAZEPAM$DB00829$Nabilone has been shown to have an additive CNS depressant effect when given with either diazepam, secobarbitone sodium, alcohol or codeine.| 
NALTREXONE$DB00704$ACAMPROSATE$DB00659$Co-administration of naltrexone with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.| 
NAPROXEN$DB00788$ASPIRIN$DB00945$Concomitant administration of naproxen and aspirin is not recommended because naproxen is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations and peak plasma levels.| 
NAPROXEN$DB00788$METHOTREXATE$DB00563$Naproxen, naproxen sodium and other NSAIDs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly increasing the toxicity of methotrexate.| 
NEFAZODONE$DB01149$Cisapride$DB00604$Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
NELFINAVIR$DB05251$AMPRENAVIR$DB00701$Nelfinavir steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant amprenavir.| 
NETILMICIN$DB00955$ETHACRYNIC ACID$DB00903$Netilmicin should not be administered concomitantly with potent loop diuretics such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.| 
NEVIRAPINE$DB00238$Ketoconazole$DB01026$Nevirapine and ketoconazole should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.| 
NEVIRAPINE$DB00238$RIFAMPIN$DB01045$Nevirapine and rifampin should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.| 
Nimbex$DB00565$SUCCINYLCHOLINE$DB00202$Administration of 0.1-mg/kg (2 x ED95) NIMBEX at 10% or 95% recovery following an intubating dose of succinylcholine (1 mg/kg) produced ?95% neuromuscular block.| 
NITROGLYCERIN$DB00727$CAPTOPRIL$DB01197$therefore, nitroglycerin or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.| 
NITROGLYCERIN$DB00727$INOmax$DB00435$Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.| 
NOREPINEPHRINE$DB00368$NOREPINEPHRINE$DB00368$Norepinephrine - Amphetamines enhance the adrenergic effect of norepinephrine.| 
NORETHINDRONE$DB00717$GABAPENTIN$DB00996$The Cmax of norethindrone was 13% higher when it was coadministered with gabapentin;| 
NORFLOXACIN$DB01059$THEOPHYLLINE$DB00277$There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline.| 
NORFLOXACIN$DB01059$Tikosyn$DB00204$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
Norpace$DB00280$QUINIDINE$DB00908$Concomitant administration of Norpace and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.| 
Oxyphenbutazone$DB03585$ASPIRIN$DB00945$Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| 
PAROXETINE$DB00715$ATOMOXETINE$DB00289$In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.| 
PAROXETINE$DB00715$CLOZAPINE$DB00363$Paroxetine produced only minor changes in the levels of clozapine and its metabolites.| 
PAROXETINE$DB00715$DULOXETINE$DB00476$Paroxetine (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.| 
Peganone$DB00754$PHENACEMIDE$DB01121$Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| 
Peganone$DB00754$Phenurone$DB01121$Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.| 
Pegasys$DB00008$THEOPHYLLINE$DB00277$Treatment with PEGASYS once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in theophylline AUC.| 
PENTAZOCINE, (-)-$DB00652$Levo-Dromoran$DB00854$Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.| 
PHENOBARBITAL$DB01174$ASPIRIN$DB00945$Phenobarbital: Decreases aspirin effectiveness by enzyme induction.| 
PHENOBARBITAL$DB01174$BEXAROTENE$DB00307$Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| 
PHENOBARBITAL$DB01174$CALCITRIOL$DB00136$Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| 
PHENOBARBITAL$DB01174$CLONAZEPAM$DB01068$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| 
PHENOBARBITAL$DB01174$EXEMESTANE$DB00990$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.| 
PHENOBARBITAL$DB01174$FELBAMATE$DB00949$Phenobarbital: It appears that phenobarbital may reduce plasma felbamate concentrations.| 
PHENOBARBITAL$DB01174$Fenoprofen$DB00573$Chronic administration of phenobarbital, a known enzyme inducer, may be associated with a decrease in the plasma half-life of fenoprofen.| 
PHENOBARBITAL$DB01174$Nalfon$DB00573$When phenobarbital is added to or withdrawn from treatment, dosage adjustment of Nalfon may be required.| 
PHENOBARBITAL$DB01174$PHENOBARBITAL$DB01174$Phenobarbital - Amphetamines may delay intestinal absorption of phenobarbital;| 
PHENOBARBITAL$DB01174$SAQUINAVIR MESYLATE$DB01232$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
PHENOBARBITAL$DB01174$SAQUINAVIR$DB01232$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
PHENYLBUTAZONE$DB00812$ASPIRIN$DB00945$Pyrazolone Derivatives (phenylbutazone, oxyphenbutazone, and possibly dipyrone): Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration.| 
PHENYLBUTAZONE$DB00812$Etodolac$DB00749$Phenylbutazone Phenylbutazone causes increase (by about 80%) in the free fraction of etodolac.| 
PHENYTOIN$DB00252$BEXAROTENE$DB00307$Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| 
PHENYTOIN$DB00252$BUSULFAN$DB01008$Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase.| 
PHENYTOIN$DB00252$CALCITRIOL$DB00136$Phenytoin/Phenobarbital: The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of vitamin D, but may reduce endogenous plasma levels of calcitriol/ergocalcitriol by accelerating metabolism.| 
PHENYTOIN$DB00252$CIPROFLOXACIN$DB00537$Phenytoin Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.| 
PHENYTOIN$DB00252$CLONAZEPAM$DB01068$Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.| 
PHENYTOIN$DB00252$DOXYCYCLINE$DB00254$Barbiturates, carbamazepine, and phenytoin decrease the half-life of doxycycline.| 
PHENYTOIN$DB00252$ESTAZOLAM$DB01215$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| 
PHENYTOIN$DB00252$EXEMESTANE$DB00990$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.| 
PHENYTOIN$DB00252$FELBAMATE$DB00949$Effects of Other Antiepileptic Drugs on Felbatol? Phenytoin: Phenytoin causes an approximate doubling of the clearance of Felbatol? (felbamate) at steady state and, therefore, the addition of phenytoin causes an approximate 45% decrease in the steady-state trough concentrations of Felbatol? as compared to the same dose of Felbatol? given as monotherapy.| 
PHENYTOIN$DB00252$FLUOROURACIL$DB00544$Concomitant administration of phenytoin and ERGAMISOL? plus fluorouracil has lead to increased plasma levels of phenytoin.| 
PHENYTOIN$DB00252$Norpace$DB00280$If phenytoin or other hepatic enzyme inducers are taken concurrently with Norpace or Norpace CR, lower plasma levels of disopyramide may occur.| 
PHENYTOIN$DB00252$SAQUINAVIR MESYLATE$DB01232$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
PHENYTOIN$DB00252$SAQUINAVIR$DB01232$Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.| 
PHENYTOIN$DB00252$SULFAPYRIDINE$DB00891$- Phenytoin (e.g., Dilantin)?Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin| 
Phospholine Iodide$DB01057$SUCCINYLCHOLINE$DB00202$Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and carbamate insecticides.| 
PIMOZIDE$DB01100$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
PIMOZIDE$DB01100$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
Pletal$DB01166$Ketoconazole$DB01026$Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.| 
Ponstel$DB00784$ASPIRIN$DB00945$Aspirin: As with other NSAIDs, concomitant administration of Ponstel and aspirin is not generally recommended because of the potential of increased adverse effects.| 
Ponstel$DB00784$FUROSEMIDE$DB00695$During concomitant therapy of Ponstel with furosemide, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy.| 
POTASSIUM$DB01345$ENALAPRIL$DB00584$Potassium sparing agents should generally not be used in patients with heart failure receiving enalapril.| 
POTASSIUM$DB01345$Prinivil$DB00722$Potassium sparing agents should generally not be used in patients with heart failure who are receiving PRINIVIL.| 
Prinivil$DB00722$LITHIUM CATION$DB01356$It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.| 
Prinivil$DB00722$LITHIUM$DB01356$It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium.| 
Prinivil$DB00722$TRIAMTERENE$DB00384$Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.| 
PROBENECID$DB01032$ACETAMINOPHEN$DB00316$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$ACYCLOVIR$DB00787$Co-administration of probenecid with acyclovir has been shown to increase the mean half-life and the area under the concentration-time curve.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$ADENOSINE PHOSPHATE$DB00415$Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| 
PROBENECID$DB01032$AMINOSALICYLIC ACID$DB00233$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$AMPICILLIN$DB00415$Probenecid: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.| 
PROBENECID$DB01032$BUMETANIDE$DB00887$- Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide.| Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| This antagonistic effect of probenecid on bu-metanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.| Thus, probenecid should not be administered concurrently with bumetanide.| 
PROBENECID$DB01032$CEFDINIR$DB00535$Probenecid As with other b span class= c233 -lactam antibiotics, probenecid inhibits the renal excretion of cefdinir, resulting in an approximate doubling in A.C. a 54% increase in peak cefdinir plasma levels, and a 50% prolongation in the apparent elimination half-life.| 
PROBENECID$DB01032$CIPROFLOXACIN$DB00537$Probenecid Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.| 
PROBENECID$DB01032$CLOFIBRATE$DB00636$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$FAMOTIDINE$DB00927$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$FUROSEMIDE$DB00695$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$METHOTREXATE$DB00563$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$NAPROXEN$DB00788$Probenecid given concurrently increases naproxen anion plasma levels and extends its plasma half-life significantly.| 
PROBENECID$DB01032$NORFLOXACIN$DB01059$Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin.| 
PROBENECID$DB01032$PENCICLOVIR$DB00299$Concurrent use with probenecid or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of penciclovir.| 
PROBENECID$DB01032$THEOPHYLLINE$DB00277$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROBENECID$DB01032$ZIDOVUDINE$DB00495$Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).| 
PROPANTHELINE$DB00782$DIGOXIN$DB00390$Propantheline and diphenoxylate, by decreasing gut motility, may increase digoxin absorption.| 
PROPOXYPHENE$DB00647$ALPRAZOLAM$DB00404$Propoxyphene: Coadministration of propoxyphene decreased the maximum plasma concentration of alprazolam by 6%, decreased clearance by 38%, and increased half-life by 58%.| 
PSEUDOEPHEDRINE$DB00852$KAOLIN$DB01575$Antacids increase the rate of absorption of pseudoephedrine, while kaolin decreases it.| 
PYRIDOXINE$DB00165$Hexalen$DB00488$however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1| 
QUINIDINE$DB00908$ARIPIPRAZOLE$DB01238$Aripiprazole dose should be reduced to one-half of its normal dose when concomitant administration of quinidine with aripiprazole occurs.| 
QUINIDINE$DB00908$DIGOXIN$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
QUINIDINE$DB00908$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
QUINIDINE$DB00908$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
QUININE$DB00468$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
QUININE$DB00468$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
QUININE$DB00468$Tikosyn$DB00204$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
RANITIDINE$DB00863$ALENDRONIC ACID$DB00630$Intravenous ranitidine was shown to double the bioavailability of oral alendronate.| 
RANITIDINE$DB00863$CEFTIBUTEN$DB01415$however, 150 mg of ranitidine q12h for 3 days increased the ceftibuten C max by 23% and ceftibuten AUC by 16%.| 
RANITIDINE$DB00863$Cisapride$DB00604$The gastrointestinal absorption of cimetidine and ranitidine is accelerated when they are coadministered with cisapride.| 
RESERPINE$DB00206$Zebeta$DB00612$Patients receiving catecholamine-depleting drugs, such as reserpine or guanethidine, should be closely monitored, because the added beta-adrenergic blocking action of ZEBETA may produce excessive reduction of sympathetic activity.| 
RETINOL$DB00162$ACITRETIN$DB00459$Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.| 
Revia$DB00704$DISULFIRAM$DB00822$The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.| 
RIFABUTIN$DB00615$Crixivan$DB00224$Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.| 
RIFAMPIN$DB01045$BEXAROTENE$DB00307$Furthermore, rifampin, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.| 
RIFAMPIN$DB01045$DIGOXIN$DB00390$Rifampin may decrease serum digoxin concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of digoxin.| 
RIFAMPIN$DB01045$DILTIAZEM$DB00343$Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels.| 
RIFAMPIN$DB01045$ESTAZOLAM$DB01215$While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.| 
RIFAMPIN$DB01045$EXEMESTANE$DB00990$Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John?s wort) may significantly decrease exposure to exemestane.| 
RIFAMPIN$DB01045$Gleevec$DB00619$Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of Gleevec, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).| 
RIFAMPIN$DB01045$HALOPERIDOL$DB00502$Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.| 
RIFAMPIN$DB01045$Ketoconazole$DB01026$Concomitant administration of rifampin with ketoconazole tablets reduces the blood levels of the latter.| 
RIFAMPIN$DB01045$SAQUINAVIR MESYLATE$DB01232$Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.| 
RIFAMPIN$DB01045$SAQUINAVIR$DB01232$Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.| 
RIFAMPIN$DB01045$Zebeta$DB00612$Concurrent use of rifampin increases the metabolic clearance of ZEBETA, resulting in a shortened elimination half-life of ZEBETA.| 
RIFAMPIN$DB01045$Zopiclone$DB01198$Drugs That Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.| 
RISPERIDONE$DB00734$LEVODOPA$DB01235$Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may reduce the therapeutic effects of levodopa.| 
RITONAVIR$DB00503$Cisapride$DB00604$Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
RITONAVIR$DB00503$Foscavir$DB00529$Abnormal renal function has been observed in clinical practice during the use of FASCAVIR and ritonavir, or FOSCAVIR, ritonavir, and saquinavir.| 
Robinul$DB00986$POTASSIUM CHLORIDE$DB00761$Concomitant administration of Robinul Injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.| 
SAQUINAVIR MESYLATE$DB01232$AMPRENAVIR$DB00701$Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.| 
SAQUINAVIR$DB01232$AMPRENAVIR$DB00701$Saquinavir steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant amprenavir.| 
SILDENAFIL$DB00203$INDINAVIR ANHYDROUS$DB00224$Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.| 
SILDENAFIL$DB00203$INDINAVIR$DB00224$Sildenafil dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant indinavir therapy.| 
Sonata$DB00962$ALCOHOL$DB00898$CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.| 
Sonata$DB00962$CIMETIDINE$DB00501$Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.| 
Sonata$DB00962$ZALEPLON$DB00962$Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.| 
SPIRONOLACTONE$DB00421$DIGOXIN$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
SUCCINYLCHOLINE$DB00202$Brevibloc$DB00187$The onset of neuromuscular blockade by succinylcholine was unaffected by BREVIBLOC, but the duration of neuromuscular blockade was prolonged from 5 minutes to 8 minutes.| 
SULFASALAZINE$DB00795$DIGOXIN$DB00390$Antacids, kaolin-pectin, sulfasalazine, neomycin, cholestyramine, certain anticancer drugs, and metoclopramide may interfere with intestinal digoxin absorption, resulting in unexpectedly low serum concentrations.| 
SUMATRIPTAN SUCCINATE$DB00669$ESCITALOPRAM OXALATE$DB01175$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN SUCCINATE$DB00669$ESCITALOPRAM$DB01175$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN SUCCINATE$DB00669$FLUVOXAMINE$DB00176$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN SUCCINATE$DB00669$PAROXETINE$DB00715$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN SUCCINATE$DB00669$SERTRALINE$DB01104$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$ESCITALOPRAM OXALATE$DB01175$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$ESCITALOPRAM$DB01175$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$FLUVOXAMINE$DB00176$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$PAROXETINE$DB00715$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
SUMATRIPTAN$DB00669$SERTRALINE$DB01104$If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.| 
TACROLIMUS ANHYDROUS$DB00864$BOSENTAN ANHYDROUS$DB00559$Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| 
TACROLIMUS ANHYDROUS$DB00864$BOSENTAN$DB00559$Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| 
TACROLIMUS ANHYDROUS$DB00864$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
TACROLIMUS ANHYDROUS$DB00864$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
TACROLIMUS$DB00864$BOSENTAN ANHYDROUS$DB00559$Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| 
TACROLIMUS$DB00864$BOSENTAN$DB00559$Caution should be exercised if tacrolimus and bosentan are used together.| Co-administration of tacrolimus and bosentan resulted in markedly increased plasma concentrations of bosentan in animals.| 
TACROLIMUS$DB00864$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
TACROLIMUS$DB00864$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
TADALAFIL$DB00820$INDINAVIR ANHYDROUS$DB00224$Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.| 
TADALAFIL$DB00820$INDINAVIR$DB00224$Tadalafil dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant indinavir therapy.| 
Tagamet$DB00501$CHLORDIAZEPOXIDE$DB00475$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$DIAZEPAM$DB00829$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$LIDOCAINE$DB05291$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$METRONIDAZOLE$DB00916$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$NIFEDIPINE$DB01115$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$PHENYTOIN$DB00252$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tagamet$DB00501$THEOPHYLLINE$DB00277$Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.| 
Tambocor$DB01195$DIGOXIN$DB00390$During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose.| 
TAMOXIFEN$DB00675$ANASTROZOLE$DB01217$Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY ? Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).| 
Targretin$DB00307$BEXAROTENE$DB00307$Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| 
Targretin$DB00307$GEMFIBROZIL$DB01241$Concomitant administration of Targretin ? capsules and gemfibrozil resulted in substantial increases in plasma concentrations of bexarotene, probably at least partially related to cytochrome P450 3A4 inhibition by gemfibrozil.| 
TETRACYCLINE$DB00759$BISMUTH SUBSALICYLATE$DB01294$Absorption of tetracycline is impaired by bismuth subsalicylate.| 
TETRACYCLINE$DB00759$DIGOXIN$DB00390$Erythromycin and clarithromycin (and possibly other macrolide antibiotics) and tetracycline may increase digoxin absorption in patients who inactivate digoxin by bacterial metabolism in the lower intestine, so that digitalis intoxication may result.| 
TETRACYCLINE$DB00759$METHOXYFLURANE$DB01028$The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| 
TETRACYCLINE$DB00759$Penthrane$DB01028$The concurrent use of tetracycline and Penthrane (methoxyflurane) has been reported to result in fatal renal toxicity.| 
THEOPHYLLINE$DB00277$ENOXACIN$DB00467$Theophylline-related adverse effects have occurred in patients when theophylline and enoxacin were coadministered.| 
THEOPHYLLINE$DB00277$ERYTHROMYCIN$DB00199$In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient is receiving concomitant erythromycin therapy.| 
THEOPHYLLINE$DB00277$FLUVOXAMINE$DB00176$Therefore, if theophylline is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.| 
THEOPHYLLINE$DB00277$Lansoprazole$DB00448$Nonetheless, individual patients may require additional titration of their theophylline dosage when lansoprazole is started or stopped to ensure clinically effective blood levels.| 
THEOPHYLLINE$DB00277$Pegasys$DB00008$Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.| 
THEOPHYLLINE$DB00277$THEOPHYLLINE$DB00277$Theophylline Grepafloxacin is a competitive inhibitor of the metabolism of theophylline.| 
THIMEROSAL$DB02731$LATANOPROST$DB00654$In vitro studies have shown that precipitation occurs when eye drops containing thimerosal are mixed with latanoprost.| 
TIAGABINE$DB00906$CARBAMAZEPINE$DB00564$Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.| 
TIAGABINE$DB00906$PHENOBARBITAL$DB01174$Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| 
TIAGABINE$DB00906$PHENYTOIN$DB00252$Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.| 
TIAGABINE$DB00906$PRIMIDONE$DB00794$Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.| 
TIAGABINE$DB00906$Valproate$DB00313$Valproate: Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.| 
Tikosyn$DB00204$CIMETIDINE$DB00501$If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.| 
Tikosyn$DB00204$Verapamil$DB00661$Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.| 
TIMOLOL$DB00373$GUANFACINE$DB01018$Noncardioselective beta-blockers (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.| 
TOLBUTAMIDE$DB01124$Atromid-S$DB00636$The hypoglycemic effect of tolbutamide has been reported to increase when Atromid-S is given concurrently.| 
TRANEXAMIC ACID$DB00302$NovoSeven$DB00036$Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, aminocaproic acid) and NovoSeven.| 
Trecator$DB00609$ISONIAZID$DB00951$Trecator has been found to temporarily raise serum concentrations of isoniazid.| 
TRIAMTERENE$DB00384$DOFETILIDE$DB00204$In addition, drugs that are actively secreted via this route (e.g., triamterene, metformin and amiloride) should be co-administered with care as they might increase dofetilide levels.| 
TRIAMTERENE$DB00384$HYDROCHLOROTHIAZIDE$DB00999$Coadministration of triamterene and hydrochlorothiazide capsules resulted in a higher plasma amantadine concentration in a 61 year old man receiving amantadine (amantadine hydrochloride) 100 mg TID for Parkinsons disease.1 It is not known which of the components of triamterene and hydrochlorothiazide capsules contributed to the observation or if related drugs produce a similar response.| 
TRIAZOLAM$DB00897$DILTIAZEM$DB00343$The elimination half life of midazolam and triazolam also increased (1.5-2.5 fold) during coadministration with diltiazem.| 
TRIAZOLAM$DB00897$FLUVOXAMINE$DB00176$Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.| 
TRIAZOLAM$DB00897$SAQUINAVIR MESYLATE$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
TRIAZOLAM$DB00897$SAQUINAVIR$DB01232$Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;| 
TRIAZOLAM$DB00897$TRIAZOLAM$DB00897$Triazolam Erythromycin has been reported to decrease the clearance of triazolam and, thus, may increase the pharmacologic effect of triazolam.| 
TRIMETHOPRIM$DB00440$SULFAMETHOXAZOLE$DB01015$Trimethoprim Alone or in Combination with Sulfamethoxazole: Concomitant use of trimethoprim alone or in combination with sulfamethoxazole is contraindicated.| 
TROLEANDOMYCIN$DB01361$Cisapride$DB00604$Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.| 
VALDECOXIB$DB00580$DEXTROMETHORPHAN$DB00514$Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| 
VALDECOXIB$DB00580$FLUCONAZOLE$DB00196$Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| 
VALDECOXIB$DB00580$GLYBURIDE$DB01016$Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.| 
VALDECOXIB$DB00580$Ketoconazole$DB01026$Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with fluconazole and 38% when coadministered with ketoconazole.| 
VALDECOXIB$DB00580$PHENARSAZINE CHLORIDE$DB00514$Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.| 
VALDECOXIB$DB00580$PHENYTOIN$DB00252$Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).| Patients already stabilized on valdecoxib should be closely monitored for loss of symptom control with phenytoin coadministration.| 
Valproate$DB00313$ISONIAZID$DB00951$Valproate: A recent case study has shown a possible increase in the plasma level of valproate when co administered with isoniazid.| 
Verapamil$DB00661$DIGOXIN$DB00390$Quinidine, verapamil, amiodarone, propafenone, indomethacin, itraconazole, alprazolam, and spironolactone raise the serum digoxin concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that digitalis intoxication may result.| 
Verapamil$DB00661$DOFETILIDE$DB00204$In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of verapamil with dofetilide was associated with a higher occurrence of torsade de pointes.| 
Videx$DB00900$CIPROFLOXACIN$DB00537$Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.| 
Videx$DB00900$Factive$DB01155$Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.| 
Videx$DB00900$GANCICLOVIR$DB01004$A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).| Ganciclovir: Administration of VIDEX 2 hours prior to or concurrent with oral ganciclovir was associated with a 111 (114)% increase in the steady-state AUC of didanosine (n = 12).| 
Videx$DB00900$NORFLOXACIN$DB01059$Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.| 
Vioxx$DB00533$BENAZEPRIL$DB00542$In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.| 
Vioxx$DB00533$LITHIUM CATION$DB01356$Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.| 
Vioxx$DB00533$LITHIUM$DB01356$Thus, when VIOXX and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.| 
Vioxx$DB00533$METHOTREXATE$DB00563$At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.| Standard monitoring of methotrexate-related toxicity should be continued if VIOXX and methotrexate are administered concomitantly.| 
Vioxx$DB00533$THEOPHYLLINE$DB00277$Adequate monitoring of theophylline plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving theophylline.| 
Vistide$DB00369$AMIKACIN$DB00479$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$AMPHOTERICIN B$DB00681$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$FOSCARNET$DB00529$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$Pentamidin$DB00738$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$TOBRAMYCIN$DB00684$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vistide$DB00369$VANCOMYCIN$DB00512$Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.| 
Vitamin B12$DB00115$FOLIC ACID$DB00158$Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.| 
Wellbutrin$DB01156$Cyclophosphamide$DB00531$Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and cyclophosphamide).| 
Wellbutrin$DB01156$THEOPHYLLINE$DB00277$Drugs that Lower Seizure Threshold: Concurrent administration of WELLBUTRIN and agents (e.g., antipsychotics, other antidepressants, theophylline, systemic steroids, etc.) that lower seizure threshold should be undertaken only with extreme caution.| 
ZAFIRLUKAST$DB00549$Tikosyn$DB00204$Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.| 
ZALEPLON$DB00962$ERYTHROMYCIN$DB00199$Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.| 
Zebeta$DB00612$CLONIDINE$DB00575$In patients receiving concurrent therapy with clonidine, if therapy is to be discontinued, it is suggested that ZEBETA be discontinued for several days before the withdrawal of clonidine.| 
Zebeta$DB00612$Verapamil$DB00661$ZEBETA should be used with care when myocardial depressants or inhibitors of AV conduction, such as certain calcium antagonists (particularly of the phenylalkylamine [verapamil] and benzothiazepine [diltiazem] classes), or antiarrhythmic agents, such as disopyramide, are used concurrently.| 
ZIDOVUDINE$DB00495$PROBENECID$DB01032$Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of VISTIDE infusion.| 
ZIDOVUDINE$DB00495$STAVUDINE$DB00649$Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| 
ZIDOVUDINE$DB00495$ZIDOVUDINE$DB00495$Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.| 
